489 Risk of Intra-Tumoral Hemorrhage (ITH) in Patients With Brain Metastases Treated With Stereotactic Radiosurgery (SRS)

INTRODUCTION: Complications related to intracranial intra-tumoral hemorrhage (ITH) in patients treated with SRS are rare and often require only expectant management. However, there is uncertainty whether anticoagulation therapy (ACT) or antiplatelet therapy (APT) might increase the risk of ITH in brain metastases (BM) treated with Stereotactic Radiosurgery (SRS). METHODS: We evaluated 266 consecutive patients (1169 BMs) treated with SRS from January 1, 2020, to December 31, 2021(Retrospective review, IRB approved). Magnetic Resonance Imaging (MRI), including T1-weighted and microhemorrhage-sensitive susceptibility-weighted imaging (SWI) and gradient-recalled echo (GRE) sequences performed pre-procedure and at first follow-up were evaluated for hemorrhage by a single neuro-radiologist (TE). RESULTS: Among the 266 patients, lung (48%), breast (17%), and melanoma (15%) were the most common primaries. At the time of SRS, 55 patients (21%) were undergoing ACT and 42 patients (16%) were on APT. ITH was identified pre-SRS in 67% of patients, increasing to 78% on post-SRS imaging sequences for the entire cohort. However, there was no significant correlation between ITH and ACT (p = 0.88) or APT (p = 0.85) vs no blood thinning therapy post SRS. Multivariate analysis revealed melanoma histology, thrombocytopenia, lower marginal doses, and larger lesion size predicted ITH (p = 0.001, 0.02, 0.02, and 0.001 respectively). CONCLUSIONS: Using microhemorrhage-sensitive MRI sequences, our data demonstrated a higher incidence of intratumoral hemorrhage in BM both at baseline and post SRS relative to demonstrated using only T1-non contrast sequences However, despite using this ultrasensitive imaging modality, no correlation was observed between APT or ACT and increased ITH risk. Our data suggests that specifically stopping ACT or APT in anticipation of SRS is likely not indicated however larger prospective randomized studies are warranted.

Authors

Publication Details

Journal
Neurosurgery
Published
2025-03-14
DOI
https://doi.org/10.1227/neu.0000000000003360_489
Primary Topic
Brain Metastases and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

489 Risk of Intra-Tumoral Hemorrhage (ITH) in Patients With Brain Metastases Treated With Stereotactic Radiosurgery (SRS)

Juan Diego Alzate, Glen H. J. Stevens, Alireza Mohammad Mohammadi, Lilyana Angelov et al.
Neurosurgery
Brain Metastases and Treatment
article

489 Risk of Intra-Tumoral Hemorrhage (ITH) in Patients With Brain Metastases Treated With Stereotactic Radiosurgery (SRS)

Juan Diego Alzate, Glen H. J. Stevens, Alireza Mohammad Mohammadi, Lilyana Angelov, Matthew M. Grabowski, Samuel T. Chao, Michael Mann, Alejandro Mercado Santori, Gene H. Barnett, Erin S. Murphy, Todd Emch, John H. Suh, Wei Wei, Sol Arancibia
article en

Abstract

INTRODUCTION: Complications related to intracranial intra-tumoral hemorrhage (ITH) in patients treated with SRS are rare and often require only expectant management. However, there is uncertainty whether anticoagulation therapy (ACT) or antiplatelet therapy (APT) might increase the risk of ITH in brain metastases (BM) treated with Stereotactic Radiosurgery (SRS). METHODS: We evaluated 266 consecutive patients (1169 BMs) treated with SRS from January 1, 2020, to December 31, 2021(Retrospective review, IRB approved). Magnetic Resonance Imaging (MRI), including T1-weighted and microhemorrhage-sensitive susceptibility-weighted imaging (SWI) and gradient-recalled echo (GRE) sequences performed pre-procedure and at first follow-up were evaluated for hemorrhage by a single neuro-radiologist (TE). RESULTS: Among the 266 patients, lung (48%), breast (17%), and melanoma (15%) were the most common primaries. At the time of SRS, 55 patients (21%) were undergoing ACT and 42 patients (16%) were on APT. ITH was identified pre-SRS in 67% of patients, increasing to 78% on post-SRS imaging sequences for the entire cohort. However, there was no significant correlation between ITH and ACT (p = 0.88) or APT (p = 0.85) vs no blood thinning therapy post SRS. Multivariate analysis revealed melanoma histology, thrombocytopenia, lower marginal doses, and larger lesion size predicted ITH (p = 0.001, 0.02, 0.02, and 0.001 respectively). CONCLUSIONS: Using microhemorrhage-sensitive MRI sequences, our data demonstrated a higher incidence of intratumoral hemorrhage in BM both at baseline and post SRS relative to demonstrated using only T1-non contrast sequences However, despite using this ultrasensitive imaging modality, no correlation was observed between APT or ACT and increased ITH risk. Our data suggests that specifically stopping ACT or APT in anticipation of SRS is likely not indicated however larger prospective randomized studies are warranted.

NeurosurgeryVol. 71(Supplement_1)
Openalex Percentile: Top 93%
Brain Metastases and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.